These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Removal of thallium by combining desferrioxamine and deferiprone chelators in rats.
    Author: Amiri A, Fatemi SJ, Fatemi SN.
    Journal: Biometals; 2007 Apr; 20(2):159-63. PubMed ID: 16927173.
    Abstract:
    The hypothesis that two known chelators deferiprone (1,2-dimethy1-3-hydroxypyrid-4-one, L1) and desferrioxamine (DFO) might be more efficient as combined treatment than as monotherapies in removing thallium from the body was tested in rats. Six-week-old male Wistar rats received chelators: L1 (p.o.), DFO (i.p.) or L1 + DFO as 110 or 220 mg/kg dose half an hour after a single i.p. administration of 8 mg Tl/kg body weight in the form of chloride. Serum thallium concentration, urinary thallium and iron excretions were determined by graphite furnace atomic absorption spectrometry. Both chelators were effective only at the higher dose level, while DFO was more effective than L1 in enhancing urinary thallium excretion, L1 was more effective than DFO in enhancing urinary iron excretion. In the combined treatment group, L1 did not increase the DFO effect on thallium and DFO did not increase the effect of L1 on iron elimination. Our results support the usefulness of this animal model for preliminary in vivo testing of thallium chelators. Urinary values were more useful because of the high variability of serum results. Result of combined chelators treatment should be confirmed in a different experimental model before extrapolation to other systems.
    [Abstract] [Full Text] [Related] [New Search]